Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 14Multiple Myeloma 8Leukemia 8Hematologic Neoplasms 8Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Graft vs Host Disease 7Lymphoma, Non-Hodgkin 6Leukemia, Myelomonocytic, Chronic 6Hodgkin Disease 6Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Primary Myelofibrosis 4Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Myeloproliferative Disorders 3Burkitt Lymphoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Prolymphocytic 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Biphenotypic, Acute 2Congenital Abnormalities 2

Interventions

fludarabine phosphate 50Cyclophosphamide 50Mycophenolic Acid 36Cyclosporine 33Busulfan 33Whole-Body Irradiation 32Peripheral Blood Stem Cell Transplantation 31Antilymphocyte Serum 24fludarabine 21Cord Blood Stem Cell Transplantation 21Tacrolimus 20Cytarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Methotrexate 13Thiotepa 10Granulocyte Colony-Stimulating Factor 10Etoposide 9Cyclosporins 7Azacitidine 7thymoglobulin 5sargramostim 5Idarubicin 5Clofarabine 5Arsenic Trioxide 5Transplantation 4Sirolimus 4Gemtuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory, with Excess of Blasts × Hematopoietic Stem Cell Transplantation × Clear all
NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
124 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
300 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡